A Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Repeated Subcutaneous Doses of SAR425899 on Energy Expenditure and Safety in Overweight to Obese Male and Female Subjects
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2018
At a glance
- Drugs SAR 425899 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Sanofi
- 09 Nov 2018 Planned End Date changed from 29 Jan 2019 to 1 Jan 2019.
- 09 Nov 2018 Planned primary completion date changed from 29 Jan 2019 to 1 Jan 2019.
- 31 Aug 2018 Biomarkers information updated